Article
Oncology
Juan Javier-DesLoges, Tyler J. Nelson, James D. Murphy, Rana R. McKay, Elizabeth Pan, J. Kellogg Parsons, Christopher J. Kane, A. Karim Kader, Ithaar H. Derweesh, Jesse Nodora, Sandip P. Patel, Maria Elena Martinez, Brent S. Rose
Summary: This study aimed to determine the representation of minorities, women, and the elderly in NCI clinical trials. The results showed that Black and Hispanic patients were underrepresented in trials, but participation rates have increased in recent years. Minority participation has increased over time, but further efforts are needed to ensure better representation.
Review
Engineering, Biomedical
Janske Nel, Kamil Elkhoury, Emilie Velot, Arnaud Bianchi, Samir Acherar, Gregory Francius, Ali Tamayol, Stephanie Grandemange, Elmira Arab-Tehrany
Summary: Despite progress in breast cancer research, it remains a leading cause of female mortality globally. Chemotherapies have limitations, such as lack of specificity and multi-drug resistance. Liposomes as drug delivery systems have potential, but few are clinically approved and none have active targeting. This review summarizes recent developments in actively targeted liposomal drug delivery systems for breast cancer.
BIOACTIVE MATERIALS
(2023)
Article
Oncology
Daiki Hara, Wensi Tao, Tulasigeri M. Totiger, Ali Pourmand, Nesrin Dogan, John Chetley Ford, Junwei Shi, Alan Pollack
Summary: This study developed PSMA-targeted gold nanoparticles to enhance prostate cancer therapy and established an X-ray fluorescence imaging system to monitor GNP delivery. Results showed enhanced tumor uptake and peak accumulation at approximately 24 hours after administration of PSMA-targeted GNPs. The XRFproj/XFCT imaging system proved to be accurate for quantifying GNPs within tumors noninvasively.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Article
Oncology
Meng-Han Tsai, Justin X. Moore, Lorriane A. Odhiambo, Sydney E. Andrzejak, Martha S. Tingen
Summary: This study examined factors associated with colorectal cancer (CRC) screening utilization among various cancer survivors. The study found that older age, recency of routine checkup, and the presence of chronic diseases were associated with CRC screening.
JOURNAL OF CANCER SURVIVORSHIP
(2022)
Article
Oncology
Selina K. Wong, Jeremy Hamm, Aria Shokoohi, Colleen E. McGahan, Cheryl Ho
Summary: Advances in curative treatment for breast, colorectal, NSCLC and prostate cancer have improved cancer survival rates. The median duration of curative treatment ranged from 6.0-26.7 weeks for the most commonly treated cancers, with some cancers requiring multimodality treatment involving both radiation and chemotherapy.
Article
Biochemical Research Methods
Yushen Jin, Chu Tang, Jie Tian, Bing Shao
Summary: Early identification and treatment of breast cancer are crucial for breast conserving therapy and improving patient prognosis. The developed Bi2S3@TaOx core-shell nanoparticles show promise as a theranostic agent for CT/photoacoustically monitored enhanced photothermal therapy, due to their high loading efficiency and excellent imaging capacities. These findings may stimulate further research into cancer therapeutic strategies using biocompatible functional nanomaterials.
BIOCONJUGATE CHEMISTRY
(2021)
Review
Oncology
Michelle Yee Mun Teo, Jung Yin Fong, Wan Ming Lim, Lionel Lian Aun In
Summary: Kirsten Rat Sarcoma (KRAS) gene somatic point mutations are highly prevalent in colorectal cancer, and targeting undruggable kinases and kinase-substrate molecules has shown promise as a therapeutic approach. Combination treatments involving MEK inhibitors and PI3K inhibitors have been shown to be effective in preventing the development of resistance and improving therapeutic outcomes in patients with metastatic colorectal cancer. Ongoing clinical trials are evaluating the use of these pathway inhibitors in combination with immunotherapy for patients with limited treatment options. This review discusses the latest scientific approaches and clinical trials targeting KRAS mutations for the management of colorectal cancer.
MOLECULAR CANCER RESEARCH
(2022)
Article
Geriatrics & Gerontology
Kunichika Matsumoto, Yosuke Hatakeyama, Kanako Seto, Ryo Onishi, Koki Hirata, Yinghui Wu, Tomonori Hasegawa
Summary: This study evaluated the relationship between the aging of the Japanese society and the disease burden by comparing the features of three cancers with different age-specific frequency rates in Japan. The social burden of breast cancer was projected to slightly increase, while that of lung cancer was expected to decrease. These findings will help prioritize future policymaking and cancer control research grants.
Article
Oncology
Chiranjeev Dash, Jiachen Lu, Vicky Parikh, Stacey Wathen, Samay Shah, Ruchi Shah Chaudhari, Lucile Adams-Campbell
Summary: The study compared colorectal cancer screening rates among breast and prostate cancer survivors in Southern Maryland, finding that factors such as living in metropolitan areas and comorbidities like obesity and diabetes were associated with lower screening rates for breast cancer survivors.
Review
Biotechnology & Applied Microbiology
Vikas, Hemendra Kumar Sahu, Abhishesh Kumar Mehata, Matte Kasi Viswanadh, Vishnu Priya, Madaswamy S. Muthu
Summary: Among all cancer types, lung cancer is considered the most lethal and highly metastatic, making targeted nanomedicine loaded with anticancer drugs essential for successful treatment. However, due to the complexity of lung cancer, the therapeutic effectiveness of single-receptor targeting nanomedicine is limited, leading to the emerging trend of dual-receptor-targeted nanomedicine. Various single- and dual-receptor-targeted nanomedicines have been developed and discussed for lung cancer treatment in this review.
Review
Pharmacology & Pharmacy
Furong Li, Yanping Lin, Rong Li, Xin Shen, Mengying Xiang, Guangrui Xiong, Ke Zhang, Tingrong Xia, Jiangyan Guo, Zhonghui Miao, Yedan Liao, Xuan Zhang, Lin Xie
Summary: Colorectal cancer is the third leading cause of cancer-related deaths, primarily due to metastasis. Targeted therapy has become the preferred option for individualized and comprehensive treatment, but managing these patients remains a challenge. Advances in precision diagnosis and sequencing technology have led to the discovery of rare molecular targets, with new therapeutic drugs actively being investigated.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Oncology
Nicola Personeni, Valeria Smiroldo, Emilio Francesco Giunta, Maria Giuseppina Prete, Lorenza Rimassa, Giacomo Bregni, Francesco Sclafani
Summary: Metastatic colorectal cancer (mCRC) poses significant challenges in cancer management, but advancements in precision medicine have led to more personalized treatment strategies. Innovative research on molecular pathways and emerging biomarkers is driving the development of targeted therapies for refractory mCRC, enhancing prognosis and treatment outcomes.
Review
Oncology
Shuangli Zhu, Yuze Wu, Bin Song, Ming Yi, Yuheng Yan, Qi Mei, Kongming Wu
Summary: Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer, lacks expression of estrogen receptor, progesterone receptor, and HER2. Although chemotherapy is the main treatment for TNBC, its effectiveness is limited. Various targeted therapies, including inhibitors of the PI3K/AKT/mTOR pathway, epidermal growth factor receptor inhibitors, Notch inhibitors, poly ADP-ribose polymerase inhibitors, and antibody-drug conjugates, have emerged. Additionally, immune checkpoint inhibitors such as pembrolizumab, atezolizumab, and durvalumab, are being extensively investigated. This review summarizes recent advances in targeted therapy and immunotherapy in TNBC, aiming to serve as a reference for future development of personalized treatment for TNBC patients.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2023)
Review
Oncology
Lejla Koco, Harm H. A. Weekenstroo, Doenja M. J. Lambregts, J. P. Michiel Sedelaar, Mathias Prokop, Jurgen J. Futterer, Ritse M. Mann
Summary: Multidisciplinary team meetings have been increasingly implemented in cancer care worldwide, with significant impacts on treatment decisions, patient outcomes, and process outcomes despite being time-consuming and expensive. Further high-quality research is needed to explore the impact of these meetings on healthcare quality.
Article
Health Care Sciences & Services
Denis Horgan, Anne-Marie Baird, Mark Middleton, Zhasmina Mihaylova, Jan P. Van Meerbeeck, Jens Vogel-Claussen, Paul E. Van Schil, Josep Malvehy, Paolo Antonio Ascierto, France Dube, Michael Zaiac, Jonathan A. Lal, Grazyna Kaminska-Winciorek, Marco Donia, Thierry Andre, Marta Kozaric, Pia Osterlund, Dan Lucian Dumitrascu, Luca Bertolaccini
Summary: Cancer remains the second leading cause of death in EU countries, and there are various challenges to be addressed, such as uneven take-up, resource limitations, lack of widespread beneficial practices, and inadequate attention to patients' quality of life. This paper, based on expert workshops, aims to plan a way forward, taking into account the unique characteristics of Europe and its constituent countries.
Article
Oncology
Vijaya R. Bhatt, Christopher Wichman, Thuy T. Koll, Alfred L. Fisher, Tanya M. Wildes, Ann Berger, James O. Armitage, Sarah A. Holstein, Lori J. Maness, Krishna Gundabolu
Summary: A study on older adults with AML receiving chemotherapy showed significant comorbidity burden and functional impairments at baseline, but cognitive and physical function improvements or stability, as well as improved depression scores, were observed in a high proportion of patients at three months post-treatment, indicating success of treatment.
JOURNAL OF GERIATRIC ONCOLOGY
(2024)
Correction
Oncology
Darren J. Walsh, Laura J. Sahm, Michelle O'Driscoll, Bronagh Bolger, Hitam Ameen, Michelle Hannan, Caitriona Goggin, Anne M. Horgan
JOURNAL OF GERIATRIC ONCOLOGY
(2024)
Article
Oncology
Eva Futtrup Maksten, Lasse Hjort Jakobsen, Boris Modrau, Hilde Jensvoll, Kristian Hay Kragholm, Judit Meszaros Jorgensen, Michael Roost Clausen, Robert Schou Pedersen, Andriette Dessau-Arp, Thomas Stauffer Larsen, Christian Bjorn Poulsen, Anne Ortved Gang, Peter Brown, Tarec C. El-Galaly, Marianne Tang Severinsen
Summary: The risk of developing dementia is not increased after lymphoma treatment among patients.
JOURNAL OF GERIATRIC ONCOLOGY
(2024)
Review
Oncology
P. A. L. Nelleke Seghers, Marije E. Hamaker, Shane O'Hanlon, Johanneke E. A. Portielje, Hans Wildiers, Pierre Soubeyran, Annemarie Coolbrandt, Siri Rostoft
Summary: This study identified a core set of symptoms to monitor in older patients with multimorbidity treated for cancer. These symptoms include those related to cancer, treatment side effects, functional decline, and destabilization of comorbidities. The results provide a basis for guiding symptom monitoring during cancer treatment.
JOURNAL OF GERIATRIC ONCOLOGY
(2024)